2627-35-2

Usage

Uses

Used in Pharmaceutical Industry:
MONO-N-DODECYL PHOSPHATE is used as a specific agonist at EDG-4 (LPA2) receptor for [application reason]. It has an EC50 value of 700 nM, indicating its potency in activating the receptor. This property makes it a valuable compound for studying the role of LPA receptors in various biological processes and potentially developing new therapeutic strategies.
Additionally, MONO-N-DODECYL PHOSPHATE is used as an antagonist at EDG-7 receptor for [application reason]. This dual functionality allows researchers to explore the effects of both activation and inhibition of LPA receptors, which could lead to a better understanding of their role in disease mechanisms and the development of targeted treatments.

InChI:InChI=1/C12H27O4P/c1-2-3-4-5-6-7-8-9-10-11-12-16-17(13,14)15/h2-12H2,1H3,(H2,13,14,15)

Upstream product

• 27460-02-2 phosphoric acid dodecyl ester-diphenyl ester 
• 112-53-8 1-dodecyl alcohol 
• 57499-93-1 1-((1-((1-butoxy-2-propanyl)oxy)-2-propanyl)oxy)-2-propanol 
• 86119-84-8 phosphoric acid 
• 144676-17-5 Phosphorous acid di-tert-butyl ester dodecyl ester 
• 362621-87-2 dibenzyl dodecyl phosphate 
• 107-46-0 Hexamethyldisiloxane 

Downstream Products

• 54653-11-1 dodecyl benzyl phosphate 
• 7423-32-7 sodium dodecyl phosphate 

Relevant academic research and scientific papers

Synthesis of a Novel Acceptor Substrate for a Mannosyl Transferase

Two novel analogues of the mannosyl transferase acceptor substrate (GlcNAc)2-pyrophosphate-dolichyl 2 have been prepared in which dolichyl is replaced by phytanyl 4 and lauryl 5; both 4 and 5 were synthesized using readily available chitin as the disaccharide precursor.

Syntheses, structures and properties of two new organic-inorganic hybrid materials based on ε-Zn Keggin units {ε-PMoV8MoVI4O40-x(OH)xZn4}

Two novel organic-inorganic hybrids, Na[PMoV8MoVI4O38(OH)2Zn4][pyim]2·1.5H2O [ε(pyim)2] (pyim = 2-(2-pyridyl)-imidazole) and [PMoVsub

A novel dumbbell-like polyoxometalate assembled of copper(II)-disubstituted monovacant Keggin polyoxoanions with a tetranuclear copper cluster

A dimeric Keggin polyoxometalate, [Cu(bpy)(μ2-OH)] 4[(H2O)(bpy)2HPW11Cu 2O39]2·2CH3CH 2OH·10H2O (1), constructed from two dicopper(II)-substituted monovacant Keggin polyoxoanions bridged by a Cu 4 cluster, has been hydrothermally synthesized. Magnetic analysis indicates predominantly an antiferromagnetic interaction between copper(II) centers. Compound 1 also shows very high catalytic activity for the esterification of phosphoric acid with equimolar lauryl alcohol to monoalkyl phosphate ester.

PHOSPHORUS-BASED RELEASING AGENT, OPTICAL POLYMERIZABLE COMPOSITION COMPRISING SAME AND PREPARATION THEREOF

Embodiments relate to a polymerizable composition comprising a phosphorus-based mold releasing agent for an optical use whose preparation process is improved, and a process for preparing the phosphorus-based mold releasing agent. The phosphorus-based mold releasing agents can be prepared more easily and conveniently by using phosphorous pentoxide, which can easily react with a monoalcohol and/or water at room temperature in the absence of a catalyst or a solvent. In addition, byproducts are not generated during the reaction. Thus, when a lens is produced by using the mold release agent obtained therefrom, it is possible to prevent a defective appearance of the lens that may be caused by byproducts, thereby further enhancing the appearance properties thereof. Further, since separate steps for removing byproducts, specifically, such steps as washing and filtration, are not required, wastewater is not generated. Thus, it is not only environmentally friendly, but the production cost can also be reduced as the process is simple.

Internal release agent, composition including internal release agent, and process for producing a plastic lens using same composition

An internal release agent includes at least one phosphodiester represented by the following general formula (1). In the formula, R1 and R2 independently represent a hydrocarbon group having 1 to 30 carbon atoms, which is optionally substituted with at least one hydroxyl group, and R3 represents an alkylene group having 2 to 4 carbon atoms. A plurality of R3's may be the same as or different from each other. M represents a hydrogen atom, an ammonium ion, an alkali metal ion, or a monovalent/divalent alkali earth metal ion, and n is an integer of 1 to 60.

Two novel bi-functional hybrid materials constructed from POMs and a Schiff base with excellent third-order NLO and catalytic properties

The first polyoxometalates modified by a porphyrin-resembling planar Schiff base have been successfully designed and synthesized under hydrothermal conditions. The third-order NLO responses indicated that they are excellent third-order NLO materials. Their catalytic performances are also investigated. The Royal Society of Chemistry.

Phospholipid-induced aggregation and anthracene excimer formation

(Chemical Equation) The zinc complex of anthryl bis(dipicolylamine) (1) aggregates upon binding with long-chain aliphatic phosphates and displays anthracene excimer fluorescence, which provides a new strategy toward detection of the biologically important lysophosphatidic acid in aqueous solution.

Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors

A more complete understanding of the physiological and pathological role of lysophosphatidic acid (LPA) requires receptor subtype-specific agonists and antagonists. Here, we report the synthesis and pharmacological characterization of fatty alcohol phosphates (FAP) containing saturated hydrocarbon chains from 4 to 22 carbons in length. Selection of FAP as the lead structure was based on computational modeling as a minimal structure that satisfies the two-point pharmacophore developed earlier for the interaction of LPA with its receptors. Decyl and dodecyl FAPs (FAP-10 and FAP-12) were specific agonists of LPA2 (EC50 = 3.7 ± 0.2 μM and 700 ± 22 nM, respectively), yet selective antagonists of LPA3 (Ki = 90 nM for FAP-12) and FAP-12 was a weak antagonist of LPA1. Neither LPA1 nor LPA3 receptors were activated by FAPs; in contrast, LPA2 was activated by FAPs with carbon chains between 10 and 14. Computational modeling was used to evaluate the interaction between individual FAPs (8 to 18) with LPA2 by docking each compound in the LPA binding site. FAP-12 displayed the lowest docked energy, consistent with its lower observed EC50. The inhibitory effect of FAP showed a strong hydrocarbon chain length dependence with C12 being optimum in the Xenopus laevis oocytes and in LPA3-expressing RH7777 cells. FAP-12 did not activate or interfere with several other G-protein-coupled receptors, including S1P-induced responses through S1P1.2,3.5 receptors. These data suggest that FAPs are ligands of LPA receptors and that FAP-10 and FAP-12 are the first receptor subtype-specific agonists for LPA2.

LPA receptor agonists and antagonists and methods of use

The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, and treating a wound.

LPA receptor agonists and antagonists and methods of use

The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA receptor, modulating LPA receptor activity, treating cancer, enhancing cell proliferation, treating a wound, treating apoptosis or preserving or restoring function in a cell, tissue, or organ, culturing cells, preserving organ or tissue function, and treating a dermatological condition.